You are here

  • Home
  • Archive
  • Volume 79, Issue 11
  • Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al

Article info

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al
Free

Authors

  • Mandana Nikpour Department of Medicine, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia Department of Rheumatology, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia PubMed articlesGoogle scholar articles
  • Molla Huq Department of Medicine, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia Department of Rheumatology, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia PubMed articlesGoogle scholar articles
  • Shereen Oon Department of Medicine, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia Department of Rheumatology, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Mandana Nikpour, Department of Medicine, University of Melbourne, Fitzroy, VIC 3010, Australia; m.nikpour{at}unimelb.edu.au
View Full Text

Citation

Nikpour M, Huq M, Oon S
Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al
Annals of the Rheumatic Diseases 2020;79:e149.

Publication history

  • Received June 24, 2019
  • Accepted June 25, 2019
  • First published July 8, 2019.
Online issue publication 
October 12, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.